Patent for Sale:

Therapeutic for the Prevention and Treatment of Alzheimer's Disease and other Neurological Disorders    

A natural and semi-modified formula that has shown to reverse AD symptoms in humans in pre-clinical tests.

Overview

A phytochemical based formula that reverses and prevents symptoms of Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, TMI, and schizophrenia. The semi-modified (electrophilically enhanced) form is already patented and non-modified are in process. This therapeutic has already been through in silica work and animal studies. It is waiting for the final human clinical (less than one year) to be ready to be released as a medical food. In pre-clinical work, this therapeutic has reversed Apraxia in Alzheimer's patients. The semi-modified version can be taken further through the pharmaceutical route. The native formula can be offered as a medical food or supplement. The therapeutic works by down regulating or up regulating several key metabolic control points involved in neurotransmitter breakdown, neurotransmitter exitotoxicity, tau formation, amyloid plaque formation, and inflammation.

Primary Application of the Technology

Those persons with neurological disease of the class Alzheimer's, Parkinson's, Huntington's Diseases and Traumatic Head Injury and schizophrenia. Those persons in any stage of Alzheimer's. Those person's with non-Alzheimer's dementia such as mild cognitive decline.

The Problem Solved by the Technology

Alzheimer’s Association reports there are currently 5 drugs being marketed for Alzheimer’s: Aricept (Donepezil), Razadyne (Galantamine), Namenda (Memantine), Exelon (Rivastigimine), and Cognex (Tacrine). All are symptomatic treatments with poor efficacy and negative side effects. They are based on acetyl cholinesterase inhibitors (AchEIs), N-methyl D-aspartate (NMDA) recep-tor antagonists and other non-AD specific therapeutics for management of symp-toms. The recent issues with Solanezumab from Eli Lilly is indicative of the problem. No drugs for the treatment or prevention of AD currently exist. Our patented formula has shown efficacy in humans in pre-clinical work.

How the Technology Solves the Problem

A hallmark of AD neuromorphology is the development of plaques and fibril tangles which appear to disrupt normal neuro communication. There has been a long debate on whether or not either of these abundant structures found in AD patients are a cause or symptom of AD, or if one is causative of the other. There are two major research camps 1) amyloid hypothesis and 2) tau protein hypothesis.

Over half of US National Institute of Health funded AD research is directed at plaque formation. In 2005, evidence was obtained that beta amyloid protein fragments were initi-ative rather than symptomatic. Scientists have now shown that a two-molecule aggregate of beta-amyloid protein fragments may play a role in initiating the disease. Current AD research is being redirected to either secretase inhibition or beta amyloid reduction.

1. Hypothesis 1.
Abnormal processing of amyloid precursor protein (APP) yields beta amyloid protein resulting in amyloid plaques.
a. Strategy: Destroy beta amyloid
b. Strategy: Target secretase which cuts APP into beta amyloid

2. Hypothesis 2.
Tau protein which supports cell structure, deforms and aggregates into neurofibrillary tangles.
a. Strategy: Target phosphorylation of tau

In contrast, rather than inhibiting and reducing these causal factors, our therapeutic has been designed to prevent their initial formation. The molecule upon which it is based has been shown to both inhibit abnormal processing of APP and hyper-phosphorylation of tau protein and inhibits TNF alpha.

It has recently been recognized that there is a link between diabetes and AD. We independently discovered the link between insulin, carbohydrate metabolism, and AD and termed the group of related diseases Metabolic Disorder Syndrome. This discovery led to the understanding that our therapeutic could address the causative agent of Metabolic Disorder Syndrome by attacking the syndrome at a cascade point in the metabolism.

Patent Summary

U.S. Patent Classes & Classifications Covered in this listing:

Class 514: Drug, Bio-Affecting And Body Treating Compositions

This class is an integral part of Class 424. It includes the following subject matter, not provided for elsewhere: 1. Drug and bio-affecting compositions which are capable of: preventing, alleviating, treating, or curing abnormal and pathological conditions of the living body; maintaining, increasing, decreasing, limiting, or destroying a physiologic body function; diagnosing a physiological condition or state by an in vivo test; controlling or protecting an environment or living body by attracting, disabling, inhibiting, killing, modifying, repelling or retarding an animal or micro-organism. 2. Body treating compositions generally intended for deodorizing, protecting, adorning, or grooming a body. 3. Fermentates. Plant and animal extracts, or body fluids or material containing plant or animal cellular structure. 4. Compositions of this class defined in terms of specific structure; e.g., layered tablet, capsule. 5. Processes of using or preparing subject matter of the Class Definition.

Subclass 455: Chalcogen bonded directly to ring carbon of the hetero ring
Subclass 456: Bicyclo ring system having the hetero ring as one of the cyclos (e.g., chromones, etc.)